HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-27-2006, 02:47 AM   #1
Christine MH-UK
Senior Member
 
Join Date: Sep 2005
Posts: 414
Genetic step leading to her2 breast cancer development found

I won't even pretend to understand this, but I do find it encouraging that they seem to be making some progress on causes.

'Inefficient proteasomal-degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer.

Li M, Wang Y, Hung MC, Kannan P.

MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.

HER-2/neu proto-oncogene is overexpressed in about one fourth of human breast cancers. AP-2 transcription factors bind to the HER-2/neu gene promoter and activate its expression. In a striking concurrence, anomalous abundance of AP-2alpha protein or its homolog AP-2gamma is also detected with HER-2/neu protein in mammary tumor-derived cell lines. This suggests that the deregulation of AP-2 is the preceding pathogenic event and probably the pivotal one in this type of mammary carcinogenesis. We examined the process of AP-2alpha gene expression in mammary carcinoma cell lines to identify where the aberration had occurred. We found no amplification of the AP-2alpha gene. Its promoter was marginally upregulated; however, it did not significantly increase the mRNA levels. When the AP-2alpha protein was examined, a remarkable stability was seen in breast cancer cell lines MDA-MB-453 and SK-BR-3, with a half-life of over 30 hr. This is sharply higher than the approximate 1 hr observed in mammary epithelial cell line MCF-10A and murine cell line NIH 3T3. Treatment of MCF-10A and NIH 3T3 cells with the proteasome inhibitor MG-132 showed that AP-2alpha was ubiquitinated and its level significantly increased. Moreover, this increase was accompanied by elevated levels HER-2/neu protein. In contrast, weaker ubiquitination of AP-2alpha was seen in MDA-MB-453 and SK-BR-3 cancer cells, and MG-132 treatment did not raise the AP-2alpha level any further. These results uncover that unusual stability is the main mechanism that raises the levels of AP-2 proteins, and in addition, provide the first clue that defective ubiquitin-dependent proteasomal-degradation pathway is possibly the prime cause that affects the HER-2/neu gene and culminates in breast cancer.'
Christine MH-UK is offline   Reply With Quote
Old 03-27-2006, 03:08 PM   #2
Unregistered
Guest
 
Posts: n/a
Thanks Christine.

I do not understand it either -I did a search on AP2, and if it is the same AP2 it links to storage and metabolism of fats in the body which links back to the omega three six balance, ppars, leptin, insulin, inflamatory pathways etc.

All of which without really more than grasping at the shadows links back with all the other stuff I have attempted to grasp to the omega three six balance being a significant factor in HER 2 related cancers.

It is the first time I am truly tempted to pay for access to an article.

RB
  Reply With Quote
Old 03-28-2006, 04:56 AM   #3
Christine MH-UK
Senior Member
 
Join Date: Sep 2005
Posts: 414
The abstract pretty much sums up what is accessible

To me at least (fortunately, I have access to a medical library). I suppose that they will come out with some fancy was of targeting this, but for now I'll just stick with the olive oil.
Christine MH-UK is offline   Reply With Quote
Old 03-28-2006, 01:39 PM   #4
Unregistered
Guest
 
Posts: n/a
It was the use of the words "prime cause" that lead me to wonder if they have an understandable explanation for that claim.

I have been reading on fats pathways metabolism cancer etc etc for some months now. There is a great deal simply do not understand at a technical level, but I feel I am beginging to put together some sort of hazy outline.

There clearly are links between HER Fas PPars AP2 leptin......at many levels and often bidirectionally. I had not really taken much notice of AP2 until your post.

Re Olive oil - Olive oil is in there but I still am convinced the three six balance is the real key. ( Olive oil is of course a useful supplement at all sorts of levels)

Thanks

RB
  Reply With Quote
Old 03-28-2006, 04:27 PM   #5
Unregistered
Guest
 
Posts: n/a
It looks like omega three down regulates AP2 (I presume adipocte P2 is the same thing /family) (perillia is high three). How does that fit in another question but reinforces the existance of linking mechanisms. The question is who is wagging who's tail.



RB


–“ Expression of the late genes of adipocyte differentiation, peroxisome proliferator-activated receptor , adipocyte P2 and adipsin, was significantly (P < 0.05) down-regulated in epididymal fat tissue of rats that had been fed perilla oil rather than beef tallow or olive oil”

Perilla Oil Prevents the Excessive Growth of Visceral Adipose Tissue in Rats by Down-Regulating Adipocyte Differentiation1,2
http://www.nutrition.org/cgi/content...f97996923bcf59
  Reply With Quote
Old 03-28-2006, 05:08 PM   #6
Unregistered
Guest
 
Posts: n/a
Re olive v n3 discussion and cancer in general terms.

As interesting trial. Poor rats.

RB


Synergistic suppression of azoxymethane-induced foci of colonic aberrant crypts by the combination of ß-carotene and perilla oil in rats
Chihito Komaki, Masataka Okuno, Nobuhito Onogi, Hisataka Moriwaki, Toshihiko Kawamori 1, Takuji Tanaka 1, Hideki Mori 1 and Yasutoshi Muto 2

First Department of Internal Medicine 40 Tsukasa-machi, Gifu 500, Japan
1First Department of Pathology, Gifu University School of Medicine 40 Tsukasa-machi, Gifu 500, Japan

2To whom correspondence should be addressed

The modulating effect of the combined dietary feeding of ß-carotene and perilla oil, which is rich in {alpha}- olinolenic acid, on the development of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) was investigated in male F344 rats. Rats received oral administration of ß-carotene (0, 50 or 200 mg/kg body weight/day) and fed a basal diet containing either 12% olive oil, 3% perilla oil plus 9% olive oil, or 12% perilla oil. A dose-dependent suppressive effect of perilla oil was found. The numbers of ACF were 42.0 and 18.4% of those of the 12% olive oil-fed controls in the rats fed 3% perilla oil plus 9% olive oil and 12% perilla oil, respectively. The development of ACF was also reduced significantly by the addition of dietary ß-carotene in each of the oil-fed groups (P < 0.05, respectively). The suppression by the combination of ß-carotene and perilla oil was synergistic, as the numbers of ACF were 12.9 and 8.9% of those of the 12% olive oil-fed controls in ß-carotene-treated rats fed 3% perilla oil plus 9% olive oil and 12% perilla oil, respectively. P-Carotene plus perilla oil also suppressed the numbers of silver-stained nucleolar organizer regions and the expression of ras mRNA in the colonic mucosa (cell proliferation biomarkers). Following administration of ß-carotene, a significant increase in the concentration of intact ß-carotene molecules was found in the colonic mucosa, livers, and sera. However, no accumulation of retinoids was observed in the colonic mucosa, suggesting that the inhibitory effect may not be related to the provitamin A activity. These results suggest that the combination of ß-carotene and perilla oil may be useful in the prevention of colon cancer.
  Reply With Quote
Old 03-28-2006, 05:17 PM   #7
Unregistered
Guest
 
Posts: n/a
More on fats activating AP2

RB


http://www.jlr.org/cgi/content/abstr...e2=tf_ipsecsha

Journal of Lipid Research, Vol 32, 1457-1463, Copyright © 1991 by Lipid Research, Inc.

ARTICLES
Regulation of adipose cell differentiation. II. Kinetics of induction of the aP2 gene by fatty acids and modulation by dexamethasone

EZ Amri, G Ailhaud and P Grimaldi
Centre de Biochimie (CNRS-UMR 134), U.F.R. Sciences, Universite de Nice- Sophia Antipolis, France.

Fatty acids behave as activators of the aP2 gene expression in committed, lipid-free, non-terminally differentiated Ob1771 cells. Like fatty acids, dexamethasone provokes a dose-dependent accumulation of aP2 mRNA. However, fatty acids and dexamethasone act through different mechanisms to activate the aP2 gene expression since i) fatty acids and dexamethasone act in a synergistic manner; ii) the effect of dexamethasone is rapid and transient (maximal effect after 8 h), whereas that of fatty acids is slower, and maintained as long as the inducer is present and is fully reversible upon fatty acid removal; iii) the induction of the aP2 gene expression by dexamethasone does not require ongoing protein synthesis, while the response to fatty acids is completely prevented by cycloheximide; and iv) the induction of the aP2 gene expression by fatty acids but not by dexamethasone is confined to preadipocyte cell lines. This suggests that the process of activation by fatty acids, rather than the expression of the aP2 gene, is unique to adipose cells. Besides their effects on the aP2 gene, fatty acids activate the expression of the acyl CoA synthetase gene which encodes another protein involved in fatty acid metabolism. Activation of both genes by fatty acids appears not to be mediated by the CCAAT enhancer binding protein, a nuclear factor reported as transactivator of the aP2 promoter activity, since the enhancer binding protein mRNA is not expressed under these conditions.
  Reply With Quote
Old 04-04-2006, 08:43 AM   #8
Emmay
Senior Member
 
Join Date: Apr 2006
Location: Boston
Posts: 66
Ap2 and Decadron - biochem problem for Her2+ bc?

Dexamethasone is Decadron. These articles (the first one from Christine MH-UK and the immediately previous one from unregistered guest sent on 3/28 at 7:17) are so technical, I'm not sure if I'm understanding them, but does it sound like Decadron might be a problem for people with Her2+ bc? As most of us are aware, the incidence of brain mets is notable for women on Herceptin, which can often keep most of the body clear but does not cross the blood/brain barrier. Decadron is usually prescribed for women being treated for brain mets (by craniotomy or any of the radiation options) to control the swelling -- do these articles suggest that while the Decadron may be controling swelling in the brain, it may also be enabling/fortifying the AP2-alpha protein and therefore the Her2 cancer cells as well? Please can someone tell me I'm all wrong? - I hope so. I'm about as far from a biochemistry major as a person could be, but I'm trying hard to understand this.
Emmay is offline   Reply With Quote
Old 04-04-2006, 12:39 PM   #9
Christine MH-UK
Senior Member
 
Join Date: Sep 2005
Posts: 414
There have been concerns about Dexamethasone

From the U. of Chicago:

Widely used anti-nausea drug may interfere with cancer chemotherapy

March 15, 2004

A drug widely used to prevent nausea and other side effects in patients receiving chemotherapy for breast cancer may also, unfortunately, prevent the therapy from working efficiently on tumor cells, researchers from the University of Chicago report in the March 1 issue of the journal, Cancer Research.

Dexamethasone--a synthetic steroid--is routinely given to women just before they receive chemotherapy with either paclitaxel or doxorubicin, two drugs commonly used to treat breast cancer. In this laboratory study, the researchers show that pretreatment with dexamethasone reduces the ability of paclitaxel and doxorubicin to kill cancer cells.

There is more on this at:

http://www.uchospitals.edu/news/2004...315-chemo.html

The more technical Pubmed link is:
http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_docsum

There is nothing specifically her2 about this, but dexamethasone is a fatty-acid synthase inducer, when many articles on her2 (such as those by Dr. Javier Menendez at Northwestern) seem to focus on the importance of fatty acid synthase inhibition for chemosensitivity, so it might be more relevant for her2 cell lines.

Of course, nothing has been proven in people.

What are the alternatives to dexamethasone and are they less problematic? I am thinking particularly about pre-meds before taxanes, where the dexamethasone is an important part of the therapy.
Christine MH-UK is offline   Reply With Quote
Old 04-04-2006, 03:00 PM   #10
R.B.
Senior Member
 
Join Date: Mar 2006
Posts: 1,843
Since I registered I am having problems in posting. I cant paste and have lost posts midstream. Until I sort it out I'm afraid I cant post the links.

I have done a quick search on omega three and the chemo agent cited paclitaxel and doxorubicin.

Both trials suggested the omega three derivates tested had synergystic effects on the chemo agent.

At a simple level this suggests the mechaninsms of omega three derivatives are different from that of Decadron.

This raises interesting issues. Would the inhibition of fas also inhibit elongation of omega three fats (assuming it is available in diet). What would be the impact of inhibiting synthesis of omega threes.

Might decadron inhibit inflamatory omega sixes and therby restrict cancerous growth but also have negative impact in terms of restricting omega threes elonated products DHA EPA and at what cost to other organ performance, if fas blocking is not restricted to breast.

RB
R.B. is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 03:41 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter